



# Belimumab (Benlysta®) Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification  
503 Sunport Lane, Orlando, FL 32809

Phone: 1-866-503-0857

FAX: 1-888-267-3277

For Medicare Advantage Part B:

FAX: 1-844-268-7263

Please indicate:  Start of treatment: Start date \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Continuation of therapy: Date of last treatment \_\_\_\_/\_\_\_\_/\_\_\_\_

Precertification Requested By: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

### A. PATIENT INFORMATION

First Name:		Last Name:	
Address:		City:	State: ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	E-mail:	
Current Weight: _____ lbs or _____ kgs		Height: _____ inches or _____ cms	

### B. INSURANCE INFORMATION

Aetna Member ID #:	Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No
Group #:	If yes, provide ID#: _____ Carrier Name: _____
Insured:	Insured: _____
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____

### C. PRESCRIBER INFORMATION

First Name:	Last Name:	(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.		
Address:	City:	State:	ZIP:	
Phone:	Fax:	St Lic #:	NPI #:	DEA #:
UPIN:	Office Contact Name:		Phone:	
Provider E-mail:	Specialty (Check one): <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Other: _____			

### D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

<b>Place of Administration:</b> <input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office <input type="checkbox"/> Outpatient Infusion Center Phone: _____ Center Name: _____ <input type="checkbox"/> Home Infusion Center Phone: _____ Agency Name: _____ <input type="checkbox"/> Administration code(s) (CPT): _____	<b>Dispensing Provider/Pharmacy: Patient Selected choice</b> <input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy <input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Mail Order <input type="checkbox"/> Other: _____ Name: _____ Phone: _____ Fax: _____ TIN: _____ PIN: _____
---	---

### E. PRODUCT INFORMATION

Request is for Benlysta: Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_

### F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

### G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

**For All Requests**

Yes  No Does the patient have a documented diagnosis of active systemic lupus erythematosus based on American College of Rheumatology (ACR) criteria?

Yes  No Has the patient had a positive autoantibody test (anti-nuclear antibody, ANA) or anti-double stranded DNA (anti-dsDNA) test?

Yes  No Has the patient been assessed by any of the following?  
→ If yes, please indicate which one was used :  
 SELENA-SLEDAI score  
 British Isles Lupus Assessment Group (BILAG) scores  
 Physician's Global Assessment (PGA) score

Yes  No Has the patient had an insufficient response to any of the following? –  
→ If yes, please indicate which one:  
 Glucocorticoids (eg. prednisone, methylprednisolone, dexamethasone)  
 Antimalarials (eg. hydroxychloroquine)  
 Immunosuppressives (eg. azathioprine, methotrexate, mycophenolate, cyclosporine, cyclophosphamide, chlorambucil, nitrogen mustard)

Yes  No Does the patient's current therapy include any of the following: anti-malarials, corticosteroids, immunosuppressives (excluding IV cyclophosphamide) or non-steroidal anti-inflammatory drugs?

Yes  No Will the patient use belimumab (Benlysta) with other biologics or IV cyclophosphamide?

Yes  No Does the patient have active severe central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis or CNS vasculitis)?

Yes  No Does the patient have active severe lupus nephritis (proteinuria greater than 6 g/24 hour or serum creatinine greater than 2.5mg/dL) or severe active nephritis?

Continued on next page



**Belimumab (Benlysta®) Injectable  
Medication Precertification Request**

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

**Aetna Precertification Notification**  
503 Sunport Lane, Orlando, FL 32809  
**Phone:** 1-866-503-0857  
**FAX:** 1-888-267-3277

**For Medicare Advantage Part B:**  
**FAX:** 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

**G. CLINICAL INFORMATION (continued)** – Required clinical information must be completed in its entirety for all precertification requests.

- Yes  No Does the patient require hemodialysis?
- Yes  No Does the patient require high-dose prednisone greater than 100mg/day?

**For Continuation of Therapy**

- Yes  No Is there documentation of continued improvement in disease activity indicating a therapeutic response/stability of the disease?
- Yes  No Does the patient have evidence of severe renal disease?
- Yes  No Does the patient have evidence of active central nervous system lupus?

**H. ACKNOWLEDGEMENT**

**Request Completed By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.